Anti-HER2 CAR-T cells with 4-1BB and CD3ζ signaling domains and have begun a phase I/II trial to demonstrate safety and feasibility in the treatment of HER2-positive solid tumors, including NSCLC (NCT01935843) [74]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.